Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Kudos! This story reported on the costs of the drug Lucentis as well as the less expensive Avastin. The story provided quantitative information about the possible impact on vision. But we wish there information about any measurement of  the patients’ perspective on whether they are functioning better after receiving this treatment versus standard treatment While the story did include the common side effect of the drug in the study, there were other potentially important complications that were not mentioned. The story mentioned that the results reported on were from a phase III clinical trial; it included information about the number of affected eyes included in the study, and the impact on vision. The story did not engage in overt disease mongering. Several experts in the field were quoted in this story. In presenting the outcome of the study, the story mentioned in passing treatments currently used for treating diabetic macular edema. The story also mentioned the existence of another drug, Avastin, which was reported as working the same way as the study medication. (A more accurate description comparing Avastin and Lucentis is that they contain the nearly identical active ingredient but the production methods are a little different.) It would have been nice to mention that there is an on-going trial comparing the effectiveness of these two medications for the treatment of macular degeneration (not the condition which was the disease in the study reported on.) The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema. The story was very clear that this was a new use for a medication that is already on the market. The story provided some insight that the company underwriting the costs of this study had a very similar but less expensive drug which was FDA approved for other use. It would have been useful to include a little more information comparing the two medications. It might also have been nice to include some information about how the drug studied works as compared to laser treatment, the current standard. Does not appear to rely on a press release.
A Genentech Eye Treatment Is Found to Help Prevent Vision Loss in Diabetics

Over 100 residents of the apartment buildings in southeast Colorado Springs have been told to leave in recent weeks, according to Colorado Department of Public Health and Environment officials. Making matters worse, residents who left said looters broke in and took belongings they left behind. A Colorado Springs Gazette reporter witnessed a person break a window Friday  at the buildings owned by Denver-based Slipstream Properties. Attempts by the newspaper to reach company officials for comment Friday were unsuccessful. Exposure to even minute amounts of asbestos can cause lung cancer and other deadly respiratory conditions. Slipstream Properties bought the buildings in 2018, raising hope that conditions in the apartments would improve after years of disrepair and code violations. The asbestos problem arose during recent renovations. Renovation work can disturb asbestos, which decades ago was used in a variety of building materials including insulation. “We’re trying to understand how widespread this is, how many apartment complexes there are,” said Curtis Burns, field operations unit supervisor for the state health department’s asbestos unit. The building owners could face fines of $25,000 per day of noncompliance with asbestos-handling regulations, Burns said.
Asbestos, looting plague Colorado Springs apartments.

The company announced $4 million in grants and said it would support “drive through” testing at 22 hospitals. Hyundai said it would provide the tests, which have been developed by South Korea-based diagnostics company Seegene, to hospitals in cities including New Orleans, Chicago and Detroit. The COVID-19 pandemic has thrown the global auto industry into the worst tailspin since the 2008-2009 financial crisis, with consumer demand collapsing as governments have enforced lockdowns in China, Europe and the United States. Hyundai’s U.S. sales fell 43% in March due to the pandemic.

Hyundai to provide COVID 19 tests, 'drive through' testing support in U.S.